Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • CAR-T • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question
Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?
Answer from: Medical Oncologist at Academic Institution
Unfortunately, no great data yet, largely case series and retrospective observations. Our group presented data at the 2022 IMS meeting (Reyes et al., "Salvage Therapies and Clinical Outcomes After Relapse Following BCMA CAR-T in Patients with RRMM") showing a 75% ORR and median duration of response ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I think there is an additional element that we must take into account, which is cost and scarcity. Right now, we have a paucity of data on whether treating with another BCMA-directed CAR T product will result in meaningful and durable responses. Should we really be prioritizing patients with prior r...
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Excellent points through and through - the ethics ...
Excellent points through and through - the ethics ...